Chemotherapy-induced peripheral neuropathy (CINP) is one of side effects among cancer patients undergoing treatment, but cannabinoids can help. Patients with CINP often suffer from the unpleasant side effects of chemotherapy medicines, including pain from the medication. However, cannabis products possibly can act as a supplement.
Why are cannabinoids important to check?
Unfortunately, major side effects like tiredness and dizziness can be seen with several medications. They may have additional effects on the patients’ quality of life. A therapy that not only reduces symptoms but also increases well being is necessary.
In order to address this problem, a real-world study is currently underway to see whether a full-spectrum cannabis extract would be useful as a supplement for CINP patients. A prospective, non-interventional, 12-week parallel-group study involving the German Society for Pain Medicine (DGS) and Avextra intends to assess the safety and effectiveness of a THC/CBD full-spectrum extract (10mg/10mg, Jack Haze cultivar) in comparison to a non-cannabis-based comparative therapy. The study’s combined target includes neuropathic pain phenotype, sleep disruptions, pain intensity, and pain-related impairment.
The DGS’s Vice President is Dr. Michael Überall. He explained that the terpene profile of this particular cultivar was chosen because it may be relevant in treating CINP. Terpenes such nerolidol, beta-caryophyllene, and terpinolene are present in the extract.
Can cannabinoids really help with CINP?
A total of 400 adult participants with CINP and a minimum pain level will take part in the trial with cannabinoids. The study will produce data by using the online resource iDoc Live®. It can act as a basis for future therapy decisions even before formal approval examinations.
Cannabinoids may help with pain management and general wellbeing after cancer treatment. Thus, these substances from cannabis are being investigated as a supplemental therapy for CINP. A THC/CBD full-spectrum extract might be another treatment option for CINP patients if it appears to be secure and efficient in this real-world investigation. It would reduce the need for traditional drugs, which can have serious adverse effects. The results of the study could improve the quality of life for people with CINP and offer helpful insights for potential future treatment plans.